Search the Newsreel

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX

Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company …

Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?

Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, …

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX

Tema ETFs LLC has acquired a new stake of 55,384 shares in Tango Therapeutics, Inc. (NASDAQ:TNGX), valued at approximately $1.73 million. Other institutional investors have also adjusted their holdings, and company insider Adam Crystal sold 27,000 shares. Despite missing EPS estimates, analysts maintain a …

Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates

Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing

Adage Capital Management, L.P. and associated parties have disclosed a 3.44% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G/A filing. This ownership amounts to 5,600,000 shares, with both shared voting and shared dispositive power. The percentage is calculated based on …

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, primarily due to higher operating expenses and no collaboration revenues. Despite the earnings miss causing a 4.8% stock dip, TNGX shares …

Guggenheim raises Tango Therapeutics stock price target to $35

Guggenheim raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $35 from $32, maintaining a Buy rating, following the company's Q2 2026 results and plans for a Phase 3 trial. Despite the stock's significant increase over the past year, InvestingPro suggests it is …

Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes

Tango Therapeutics (TNGX) saw its stock drop by about 5% after reporting a widened net loss of US$100.9m and zero revenue for the first half of 2026, compared to US$8.6m in the prior year. Despite a significant equity raise earlier in the year, the …

Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside

Analysts have increased the average 12-month price target for Tango Therapeutics, Inc. (TNGX) stock from $44.33 to $44.58, with a range of $24 to $69 per share. This updated target suggests a 61% potential upside based on the Aug. 10 closing price. The consensus …

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) stock fell nearly 4.0% after the company reported Q2 2026 financial results that missed Wall Street expectations, with a wider net loss per share and zero revenue. Operating costs, particularly general and administrative expenses, nearly doubled year-over-year. Despite progress in clinical …

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results

Tango Therapeutics faces earnings test as PRMT5 data fuels rally

Tango Therapeutics (TNGX) is set to report its second-quarter results, with investors closely watching for updates on its PRMT5 inhibitor programs and its path to a pivotal pancreatic cancer trial. The company's stock has rallied significantly due to promising combination data, and analysts are …

Tango Therapeutics, Inc. Q2 2026: Revenue $0 Net loss $55.34M, EPS ($0.37) — 10-Q Summary

Tango Therapeutics, Inc. reported Q2 2026 financial results with $0 revenue, a net loss of $55.34 million, and a diluted EPS loss of $0.37. The company's financial performance worsened year-over-year due to increased spending on its PRMT5 programs and expanded clinical operations. Despite the …

Tango Therapeutics (Nasdaq: TNGX) posts higher loss while amassing $1B cash for oncology trials

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics announced its second-quarter 2026 financial results, highlighting a pivotal period with positive Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, achieving a 92% objective response rate. The company is preparing for late-stage clinical advancement and has strengthened its leadership team …

345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. recently acquired 345,156 shares of Tango Therapeutics (NASDAQ:TNGX) worth approximately $10.79 million, giving them a 0.24% stake in the company. Other institutional investors also adjusted their positions in Tango Therapeutics, while insider Adam Crystal sold 27,000 shares for about $798,930. …

Form 8K Tango Therapeutics Inc For: 7 August By Investing.com

This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7th. It is a brief financial news update from Investing.com, highlighting the filing with the Securities and Exchange Commission (SEC). The article also notes a 6.66% decline in Tango Therapeutics' stock …

Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure

Tango Therapeutics announced that Executive Chair Dr. Barbara Weber's employment ended on August 3, 2026, and she resigned from all positions without disagreement. Her departure aligns with an amended employment agreement, and she will receive a separation package including salary continuation, COBRA reimbursement, and …

Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?

Tango Therapeutics (NASDAQ:TNGX) experienced a 6.1% decline in its share price during midday trading, closing at $27.24 with a significant 86% decrease in trading volume compared to its average. Despite the drop, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an …

Tango Therapeutics (NASDAQ: TNGX) outlines Barbara Weber separation package

Tango Therapeutics (NASDAQ: TNGX) has detailed the separation agreement with its former Executive Chair, Dr. Barbara Weber, whose employment and board roles ended on August 3, 2026. The agreement, executed on August 6, 2026, includes base-salary severance and COBRA reimbursement through December 31, 2026, …

Certain Stock Options of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026.

Certain stock options of Tango Therapeutics, Inc. (TNGX) are under a 60-day lock-up agreement, preventing sales or transfers from June 9, 2026, until August 8, 2026. This restriction applies to directors and executive officers and covers common stock and convertible securities. The agreement aims …

Tango Therapeutics executive chair Barbara Weber steps down, exits board

Barbara Weber has stepped down as Executive Chair of Tango Therapeutics and exited her board seat, effective August 3, 2026. The company stated that her departure was not due to any disagreements regarding company operations, practices, or policies. This news was generated by AI …

Tango Therapeutics stock surges 45% on pancreatic cancer data

Tango Therapeutics' stock surged 45% after announcing positive initial data from its Phase 1/2 trial for a pancreatic cancer treatment. A combination of vopimetostat and daraxonrasib showed a 92% objective response rate and 90% 6-month progression-free survival in patients with MTAP-deleted and RAS-mutant pancreatic …

Tango Therapeutics, Inc. (TNGX) president exercises options and sells shares

Crystal Adam, President, R&D at Tango Therapeutics, Inc. (TNGX), exercised stock options for 27,000 shares at $5.20 each and simultaneously sold all 27,000 shares in two tranches at weighted average prices of $26.7895 and $27.3509 per share. These transactions were executed under a Rule …

TNG Therapeutics (TNGX) insider schedules 81,000-share option-related stock sale

Adam Crystal, an insider at TNG Therapeutics Inc. (TNGX), has filed a notice to sell 81,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, following the exercise of stock options, with an aggregate value of $2,201,580.00. This filing …

Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC

Tango Therapeutics Inc (TNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Tango Therapeutics Inc (TNGX), including its current stock price and market capitalization. It attempts to present a revenue breakdown by business segment and region, but notes that this relevant data has not yet been disclosed by …

Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis

Tango Therapeutics Inc (TNGX) has a robust financial status with a score of 8.24, ranking 57th in the Biotechnology & Medical Research industry, despite a 100% year-over-year decrease in quarterly revenue and a 14.14% decrease in net profit. The analysis highlights high operating efficiency …

Tango Therapeutics Inc (TNGX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Tango Therapeutics Inc (TNGX), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and TNGX's recent performance in these areas, such as its …

Tango Therapeutics Inc (TNGX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tango Therapeutics Inc (TNGX), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activities by top firms. The report also lists related ETFs that …

TradingKey

This article provides a detailed quarterly and annual income statement for Tango Therapeutics Inc (TNGX). It includes key financial metrics such as total revenue, operating expenses, research and development expenses, operating profit, net non-operating interest income/expenses, other non-operating income/expenses, income before and after tax, …

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

Wall Street analysts project a significant upside for Tango Therapeutics (TNGX), with a mean price target suggesting a 49.5% increase. Despite some variability in individual estimates, there's strong agreement among analysts regarding the company's potential for better-than-expected earnings, reinforced by a positive trend in …